Skip to Content
  • Previous Rank
    375
  • Revenues ($M)
    9,703
  • Revenue Percent Change
    40%
  • Profits ($M)
    2,935
  • Profits Percent Change
    57.6%
  • Market Value (as of March 31, 2015)
    99,064

The biotechnology company discovers and manufactures treatments for autoimmune disorders, neurodegenerative diseases and hemophilia.

Company Info

CEO
George A. Scangos
Industry
Pharmaceuticals
Sector
Health Care
HQ Location
Cambridge, MA
Websitehttp://www.biogen.com
Years on List6
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)9,70340%
Profits ($M)2,93557.6%
Total Stockholder Equity10,809-
Employees7,550-
Market Value (as of March 31, 2015)99,064-

Profit Ratios

Profit as % of Revenues30.2%
Profits as % of Assets20.5%
Profits as % of Stockholder Equity27.2%

Earnings Per Share (last fiscal year)

Earnings Per Share ($)12.37
EPS % Change (from 2013)58.4%
EPS % Change (5 year annual rate)29.9%
EPS % Change (10 year annual rate)67.8%

Total Return

Total Return to Investors (2014)21.4%
Total Return to Investors (5 year, annualized)44.7%
Total Return to Investors (10 year, annualized)17.7%